Orbion Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 175.00 Cr
as on 01-11-2024
- Paid Up Capital ₹ 175.00 Cr
as on 01-11-2024
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 35.00 Cr
as on 01-11-2024
About Orbion Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 175.00 Cr and a paid-up capital of Rs 175.00 Cr.
The company currently has active open charges totaling ₹35.00 Cr.
The Key Managerial Personnel (KMP) at Orbion Pharmaceuticals Private Limited India is Sakthivel Ganapathy as COMPANY SECRETARY. Bajrang Garg, Mridul Dhanuka, Ashok Hegde, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100TN2021FTC143806
- Company No.
143806
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
31 May 2021
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Orbion Pharmaceuticals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Hegde  | Managing Director | 31-May-2021 | Current |
| Sakthivel Ganapathy | Company Secretary | 06-Oct-2022 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mridul Dhanuka | Director | 31-May-2021 | Current |
| Bajrang Garg | Director | 17-Aug-2021 | Current |
Phanindranath Punji  | Director | 17-Aug-2021 | Current |
Financial Performance and Corporate Structure Insights of Orbion Pharmaceuticals.
Orbion Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Orbion Pharmaceuticals?
In 2023, Orbion Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nuwill Research And Innovations Private LimitedActive 9 years 9 monthsAshok Hegde and Phanindranath Punji are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 17 Jul 2023 | ₹35.00 Cr | Open |
How Many Employees Work at Orbion Pharmaceuticals?
Orbion Pharmaceuticals has a workforce of 250 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orbion Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orbion Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
